Tangeretin, a citrus-peel plant compound sold as a dietary supplement, draws interest for laboratory and animal effects on inflammation, blood sugar, brain cells and lifespan. Human evidence is thin: small, short trials suggest a calmer stress-hormone response to hard training, less exercise-triggered airway narrowing, fewer night-time trips to urinate and possibly better blood sugar, none confirmed independently. Risks are uncertain rather than documented, centering on specific drug combinations. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Platelet count | 200–350 × 10⁹/L | Bleeding safety |
| ALT | Under 25 U/L | Liver strain |
| AST | Under 25 U/L | Liver or muscle strain |
| eGFR | Above 90 mL/min/1.73 m² | Kidney clearance |
| Fasting glucose | 75–90 mg/dL | Blood sugar effect |
| HbA1c | Under 5.4% | Three-month sugar trend |
| LDL-C | Under 100 mg/dL; under 70 mg/dL with elevated cardiovascular risk | Cholesterol claim |
| hs-CRP | Under 1.0 mg/L | Inflammation trend |
| INR (warfarin users only) | Prescriber's range (usually 2.0–3.0) | Bleeding risk |
| Morning cortisol (optional) | No established target; change from own baseline | Stress-hormone response |
Cadence: Baseline before starting; blood count, liver enzymes, fasting glucose, HbA1c and lipids repeated at 8–12 weeks, then every 6–12 months if use continues; INR within 1 week of starting or stopping (warfarin users); drug levels 1–2 weeks after any change (narrow-margin drugs)